Capstone Investment Advisors LLC raised its position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 90.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,062 shares of the biotechnology company’s stock after acquiring an additional 2,410 shares during the period. Capstone Investment Advisors LLC’s holdings in United Therapeutics were worth $1,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also modified their holdings of the company. Advisors Asset Management Inc. raised its holdings in United Therapeutics by 1.9% during the 3rd quarter. Advisors Asset Management Inc. now owns 7,847 shares of the biotechnology company’s stock valued at $1,772,000 after buying an additional 143 shares during the period. Alps Advisors Inc. raised its holdings in United Therapeutics by 7.6% during the 3rd quarter. Alps Advisors Inc. now owns 1,495 shares of the biotechnology company’s stock valued at $338,000 after buying an additional 105 shares during the period. Schroder Investment Management Group raised its holdings in United Therapeutics by 21.5% during the 3rd quarter. Schroder Investment Management Group now owns 178,005 shares of the biotechnology company’s stock valued at $40,206,000 after buying an additional 31,510 shares during the period. iA Global Asset Management Inc. purchased a new stake in United Therapeutics during the 3rd quarter valued at $607,000. Finally, Mercer Global Advisors Inc. ADV raised its holdings in United Therapeutics by 22.6% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 12,151 shares of the biotechnology company’s stock valued at $2,745,000 after buying an additional 2,237 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.
United Therapeutics Stock Up 1.1 %
Shares of UTHR traded up $3.52 during midday trading on Friday, reaching $314.56. 460,578 shares of the stock were exchanged, compared to its average volume of 607,684. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $325.00. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The company’s 50 day moving average is $282.72 and its two-hundred day moving average is $246.29. The company has a market capitalization of $13.95 billion, a P/E ratio of 14.87, a PEG ratio of 1.37 and a beta of 0.55.
Insider Activity at United Therapeutics
In related news, Director Nilda Mesa sold 266 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the sale, the director now owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Nilda Mesa sold 266 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total transaction of $84,742.28. Following the sale, the director now owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Christopher Causey sold 2,240 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the completion of the sale, the director now owns 4,185 shares of the company’s stock, valued at $1,087,723.35. The disclosure for this sale can be found here. Insiders have sold a total of 112,544 shares of company stock valued at $29,811,740 over the last quarter. 12.50% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
Several analysts recently weighed in on the company. Wells Fargo & Company increased their price target on United Therapeutics from $325.00 to $350.00 and gave the company an “overweight” rating in a report on Wednesday, June 12th. The Goldman Sachs Group increased their target price on United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. JPMorgan Chase & Co. increased their target price on United Therapeutics from $280.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 21st. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $312.22.
Check Out Our Latest Research Report on UTHR
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading
- Five stocks we like better than United Therapeutics
- With Risk Tolerance, One Size Does Not Fit All
- MarketBeat Week in Review – 7/1 – 7/5
- About the Markup Calculator
- Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?
- ETF Screener: Uses and Step-by-Step Guide
- Qualcomm Stock Continues to Rise in the Face of Negative News
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.